Brokerages expect Zymeworks Inc (NYSE:ZYME) to announce ($0.84) earnings per share for the current fiscal quarter, Zacks reports. Four analysts have provided estimates for Zymeworks’ earnings, with the highest EPS estimate coming in at ($0.30) and the lowest estimate coming in at ($1.14). Zymeworks posted earnings of $0.33 per share in the same quarter last year, which suggests a negative year-over-year growth rate of 354.5%. The business is scheduled to issue its next earnings results on Wednesday, March 4th.
According to Zacks, analysts expect that Zymeworks will report full-year earnings of ($2.79) per share for the current fiscal year, with EPS estimates ranging from ($3.39) to ($2.26). For the next fiscal year, analysts forecast that the company will report earnings of ($2.91) per share, with EPS estimates ranging from ($3.65) to ($0.65). Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side research firms that follow Zymeworks.
Zymeworks (NYSE:ZYME) last released its quarterly earnings results on Tuesday, November 5th. The company reported ($0.70) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.76) by $0.06. Zymeworks had a negative net margin of 112.95% and a negative return on equity of 25.72%. The company had revenue of $7.86 million during the quarter, compared to the consensus estimate of $7.77 million.
ZYME stock traded up $0.63 during trading on Thursday, reaching $42.86. The company had a trading volume of 386,202 shares, compared to its average volume of 235,920. Zymeworks has a 52 week low of $10.72 and a 52 week high of $45.58. The company has a market cap of $1.56 billion, a P/E ratio of -34.02 and a beta of 1.54. The business has a 50 day moving average of $37.84 and a 200 day moving average of $27.64. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.81 and a quick ratio of 6.81.
Hedge funds and other institutional investors have recently made changes to their positions in the business. Truvestments Capital LLC increased its stake in shares of Zymeworks by 100.0% during the third quarter. Truvestments Capital LLC now owns 1,000 shares of the company’s stock valued at $25,000 after purchasing an additional 500 shares in the last quarter. BlackRock Inc. increased its position in shares of Zymeworks by 42.3% during the second quarter. BlackRock Inc. now owns 1,679 shares of the company’s stock valued at $37,000 after acquiring an additional 499 shares in the last quarter. Advisor Group Inc. increased its position in shares of Zymeworks by 42.7% during the second quarter. Advisor Group Inc. now owns 1,806 shares of the company’s stock valued at $40,000 after acquiring an additional 540 shares in the last quarter. HWG Holdings LP increased its position in shares of Zymeworks by 181.2% during the third quarter. HWG Holdings LP now owns 1,732 shares of the company’s stock valued at $43,000 after acquiring an additional 1,116 shares in the last quarter. Finally, Cutler Group LP increased its position in shares of Zymeworks by 1,050.0% during the third quarter. Cutler Group LP now owns 2,300 shares of the company’s stock valued at $57,000 after acquiring an additional 2,100 shares in the last quarter. 54.28% of the stock is owned by institutional investors and hedge funds.
Zymeworks Company Profile
Zymeworks Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The company's lead product candidates include ZW25, a bispecific antibody that is in Phase I clinical trial for the treatment of breast and gastric cancer; ZW49, a bispecific antibody-drug conjugate that is in preclinical stage for treating breast and gastric cancers, and solid tumors.
Featured Story: What are earnings reports?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Zymeworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zymeworks and related companies with MarketBeat.com's FREE daily email newsletter.